
A new product for radiation-free and non-contact breast tissue screening by TiaLinx, an Irvine, California firm, is released.
The AR60-A is a laptop size, portable, and non-contact screening system designed to detect abnormal tissues in female breasts.
Advertisement
The AR60-A device emits non-ionizing electromagnetic radiation, focusing the beam using special wafer-thin panels and detecting the response using planar antennas.
The technology detects the different electrical properties of abnormal cells as compared to the healthy ones.
X-Rays accumulate radiation in the body but the 60GHz scanning technology does not emit ionizing radiation, making the AR60-A a quintessential technology for the medical field.
The technology takes advantage of the fact that different cell types have different electrical properties. The AR60-A spots abnormal cell clusters and highlights them on the screen against a blue background of normal cells.
TiaLinx plans to apply for FDA approval for the device, with the goal of submitting the application by the fourth quarter of 2015. Additionally, the product line will be spun-off into a separate new company called MamoMedix
Source: Medindia
X-Rays accumulate radiation in the body but the 60GHz scanning technology does not emit ionizing radiation, making the AR60-A a quintessential technology for the medical field.
Advertisement
The technology takes advantage of the fact that different cell types have different electrical properties. The AR60-A spots abnormal cell clusters and highlights them on the screen against a blue background of normal cells.
TiaLinx plans to apply for FDA approval for the device, with the goal of submitting the application by the fourth quarter of 2015. Additionally, the product line will be spun-off into a separate new company called MamoMedix
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News

A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.

The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.

The mechanism by which the kinases cause inflammation has been discovered by scientists.

Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.

New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.